SCHEMBL3964871

SCHEMBL3964871

O=C1Nc2cc(Cl)ccc2C1(O)c1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 2/20 0.45
BRD4 O60885 2/20 0.40
POLB P06746 1/20 0.40
CASP6 P55212 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 3/20 0.38
MDM2 Q00987 3/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
KCNMA1 Q12791 1/20 0.37
IDO1 P14902 1/20 0.36
MMP2 P08253 1/20 0.36
ADAM17 P78536 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24281862 0.83 POLB (0.48) BRD4POLBCASP6MEN1KMT2A
SCHEMBL3966468 0.82 BRD4 (0.52) BRD4POLBCASP6MEN1KMT2A
SCHEMBL15619966 0.82 KMT2A (0.58) TGM2BRD4POLBCASP6ALDH1A1
SCHEMBL3969045 0.80 BRD4 (0.49) BRD4POLBCASP6MEN1KMT2A
SCHEMBL3967431 0.75 MDM2 (0.66) TGM2MEN1KMT2ATP53MDM2
SCHEMBL3973547 0.75 POLB (0.49) BRD4POLBCASP6MEN1KMT2A
SCHEMBL3969763 0.74 TP53 (0.62) BRD4POLBCASP6KMT2ATP53
SCHEMBL3973098 0.74 IDO1 (0.42) BRD4POLBCASP6MEN1KMT2A
SCHEMBL3088648 0.74 POLB (0.37) POLBCASP6ALDH1A1MMP2ADAM17
SCHEMBL3968785 0.73 MEN1 (0.53) BRD4POLBCASP6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101203489-B Oxindole derivatives HOFFMANN LA ROCHE 2011-08-31 CN disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
US-7576082-B2 Oxindole derivatives HOFFMAN-LA ROCHE INC. (US) 2009-08-18 US disclosed
CN-101203489-A Oxindole derivatives HOFFMANN LA ROCHE (CH) 2008-06-18 CN disclosed
EP-1896412-A2 OXINDOLE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2008-03-12 EP disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
WO-2006136606-A2 OXINDOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2006-12-28 WO disclosed
US-20060293319-A1 Oxindole derivatives LUK KIM-CHUN 2006-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060293319-A1 Oxindole derivatives CCNI, OGFR, MKI67 TGM2 4434/4885BRD4 1561/4885POLB 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.